{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:33:34Z","timestamp":1784640814319,"version":"3.55.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NorthSea Therapeutics"},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007734"],"award-info":[{"award-number":["5T32HL007734"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007734"],"award-info":[{"award-number":["5T32HL007734"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["2T32DK007754-22"],"award-info":[{"award-number":["2T32DK007754-22"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","award":["Richard and Sandra Cummings Research Fellowship"],"award-info":[{"award-number":["Richard and Sandra Cummings Research Fellowship"]}],"id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006823","name":"Boston Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Parenteral (intravenous) nutrition is lifesaving for patients with intestinal failure, but long-term use of parenteral nutrition often leads to liver disease. SEFA-6179 is a synthetic medium-chain fatty acid analogue designed to target multiple fatty acid receptors regulating metabolic and inflammatory pathways. We hypothesized that SEFA-6179 would prevent hepatosteatosis and lipotoxicity in a murine model of parenteral nutrition-induced hepatosteatosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Two <jats:italic>in vivo<\/jats:italic> experiments were conducted. In the first experiment, six-week-old male mice were provided an <jats:italic>ad lib<\/jats:italic> fat-free high carbohydrate diet (HCD) for 19 days with orogastric gavage of either fish oil, medium-chain triglycerides, or SEFA-6179 at a low (0.3mmol\/kg) or high dose (0.6mmol\/kg). In the second experiment, six-week-old mice were provided an <jats:italic>ad lib<\/jats:italic> fat-free high carbohydrate diet for 19 days with every other day tail vein injection of saline, soybean oil lipid emulsion, or fish oil lipid emulsion. Mice then received every other day orogastric gavage of medium-chain triglyceride vehicle or SEFA-6179 (0.6mmol\/kg). Hepatosteatosis was assessed by a blinded pathologist using an established rodent steatosis score. Hepatic lipid metabolites were assessed using ultra-high-performance liquid chromatography-mass spectrometry. Effects of SEFA-6179 on fatty acid oxidation, lipogenesis, and fatty acid uptake in human liver cells were assessed <jats:italic>in vitro<\/jats:italic>.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>In the first experiment, mice receiving the HCD with either saline or medium-chain triglyceride treatment developed macrovesicular steatosis, while mice receiving fish oil or SEFA-6179 retained normal liver histology. In the second experiment, mice receiving a high carbohydrate diet with intravenous saline or soybean oil lipid emulsion, along with medium chain triglyceride vehicle treatment, developed macrovescular steatosis. Treatment with SEFA-6179 prevented steatosis. In each experiment, SEFA-6179 treatment decreased arachidonic acid metabolites as well as key molecules (diacylglycerol, ceramides) involved in lipotoxicity. SEFA-6179 increased both \u03b2- and complete fatty oxidation in human liver cells, while having no impact on lipogenesis or fatty acid uptake.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>SEFA-6179 treatment prevented hepatosteatosis and decreased toxic lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis. An increase in both \u03b2- and complete hepatic fatty acid oxidation may underlie the reduction in steatosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0295244","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T18:31:29Z","timestamp":1701455489000},"page":"e0295244","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-0019","authenticated-orcid":true,"given":"Bennet S.","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Fligor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian L.","family":"Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Secor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savas T.","family":"Tsikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumeng J.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria H.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy T.","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Anez-Bustillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas I.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-8268","authenticated-orcid":true,"given":"Jenny","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arild C.","family":"Rustan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Gura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7941-2926","authenticated-orcid":true,"given":"Mark","family":"Puder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"pone.0295244.ref001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10024-001-0154-7","article-title":"Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases","volume":"7","author":"E Zambrano","year":"2004","journal-title":"Pediatr Dev Pathol"},{"key":"pone.0295244.ref002","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jpeds.2012.03.062","article-title":"Natural History of Pediatric Intestinal Failure: Initial Report from the Pediatric Intestinal Failure Consortium","volume":"161","author":"RH Squires","year":"2012","journal-title":"J Pediatr"},{"key":"pone.0295244.ref003","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000000445","article-title":"The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy","volume":"261","author":"P Nandivada","year":"2015","journal-title":"Ann Surg"},{"key":"pone.0295244.ref004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpeds.2020.09.068","article-title":"Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study","volume":"230","author":"KM Gura","year":"2021","journal-title":"J Pediatr"},{"key":"pone.0295244.ref005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2020.09.023","article-title":"Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure","volume":"74","author":"A Mutanen","year":"2021","journal-title":"J Hepatol"},{"key":"pone.0295244.ref006","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.656441","article-title":"Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease","volume":"12","author":"JD Secor","year":"2021","journal-title":"Frontiers in Physiology"},{"key":"pone.0295244.ref007","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000084","article-title":"Intestinal Lipid Absorption and Lipoprotein Formation","volume":"25","author":"MM Hussain","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"pone.0295244.ref008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/0148607108314758","article-title":"Effects of Medium-Chain Triglycerides, Long-Chain Triglycerides, or 2-Monododecanoin on Fatty Acid Composition in the Portal Vein, Intestinal Lymph, and Systemic Circulation in Rats","volume":"32","author":"Y-Q Nancy You","year":"2008","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"pone.0295244.ref009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1074\/jbc.M111.294785","article-title":"Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors","volume":"287","author":"RRV Malapaka","year":"2012","journal-title":"J Biol Chem"},{"key":"pone.0295244.ref010","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1089\/dna.2020.5846","article-title":"20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?","volume":"39","author":"VB Luscombe","year":"2020","journal-title":"DNA and Cell Biology"},{"key":"pone.0295244.ref011","article-title":"A medium chain fatty acid analogue prevents intestinal failure-associated liver disease in preterm Yorkshire piglets","author":"SC Fligor","year":"2023","journal-title":"Gastroenterology"},{"key":"pone.0295244.ref012","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jpedsurg.2010.08.018","article-title":"Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model","volume":"46","author":"JA Meisel","year":"2011","journal-title":"J Pediatr Surg"},{"key":"pone.0295244.ref013","unstructured":"Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, D.C.: National Academies Press; 2011. p. 12910."},{"key":"pone.0295244.ref014","doi-asserted-by":"crossref","first-page":"e0217155","DOI":"10.1371\/journal.pone.0217155","article-title":"Alpha-tocopherol in intravenous lipid emulsions imparts hepatic protection in a murine model of hepatosteatosis induced by the enteral administration of a parenteral nutrition solution","volume":"14","author":"GL Fell","year":"2019","journal-title":"PLoS One"},{"key":"pone.0295244.ref015","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/ajcn\/nqy370","article-title":"Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added \u03b1-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury","volume":"109","author":"MA Baker","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"pone.0295244.ref016","doi-asserted-by":"crossref","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology","volume":"9","author":"W Liang","year":"2014","journal-title":"PLoS One"},{"key":"pone.0295244.ref017","doi-asserted-by":"crossref","DOI":"10.15344\/2456-8007\/2016\/102","article-title":"A Note on Exact Tests and Confidence Intervals for Two-by-Two Contingency Tables in Randomized Trials","volume":"1","author":"Y. Chiba","year":"2016","journal-title":"Int J Clin Res Trials"},{"key":"pone.0295244.ref018","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/1541-0420.00051","article-title":"A cautionary note on exact unconditional inference for a difference between two independent binomial proportions","volume":"59","author":"DV Mehrotra","year":"2003","journal-title":"Biometrics"},{"key":"pone.0295244.ref019","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/jcm10040792","article-title":"Roles of Ceramides in Non-Alcoholic Fatty Liver Disease","volume":"10","author":"E Hajduch","year":"2021","journal-title":"J Clin Med"},{"key":"pone.0295244.ref020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2020.09.023","article-title":"Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure","volume":"74","author":"A Mutanen","year":"2021","journal-title":"J Hepatol"},{"key":"pone.0295244.ref021","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jpedsurg.2021.09.018","article-title":"Long-term assessment of bilirubin and transaminase trends in pediatric intestinal failure patients during the era of hepatoprotective parenteral nutrition","volume":"57","author":"G Keefe","year":"2022","journal-title":"J Pediatr Surg"},{"key":"pone.0295244.ref022","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14740338.2021.1867099","article-title":"Current strategies for managing intestinal failure-associated liver disease","volume":"20","author":"JD Secor","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0295244.ref023","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"GI Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"pone.0295244.ref024","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/0192623312448935","article-title":"Liver Hypertrophy: A Review of Adaptive (Adverse and Non-adverse) Changes\u2014Conclusions from the 3rd International ESTP Expert Workshop","volume":"40","author":"AP Hall","year":"2012","journal-title":"Toxicol Pathol"},{"key":"pone.0295244.ref025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"K Matsusue","year":"2003","journal-title":"J Clin Invest"},{"key":"pone.0295244.ref026","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.3390\/ijms23084305","article-title":"PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients","volume":"23","author":"NF Lange","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"pone.0295244.ref027","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/ijms21062061","article-title":"PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice","volume":"21","author":"Y Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"pone.0295244.ref028","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejphar.2016.06.043","article-title":"Effects of the new thiazolidine derivative LPSF\/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD)","volume":"788","author":"S Ara\u00fajo","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"pone.0295244.ref029","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2337\/db07-0435","article-title":"Adiponectin Reduces Plasma Triglyceride by Increasing VLDL Triglyceride Catabolism","volume":"57","author":"L Qiao","year":"2008","journal-title":"Diabetes"},{"key":"pone.0295244.ref030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.bbalip.2014.10.008","article-title":"Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid","volume":"1851","author":"WS Powell","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"pone.0295244.ref031","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1111\/bph.13844","article-title":"Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease","volume":"174","author":"C Wang","year":"2017","journal-title":"Br J Pharmacol"},{"key":"pone.0295244.ref032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/ijms21010040","article-title":"Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover","volume":"21","author":"J Simon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"pone.0295244.ref033","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41418-017-0014-2","article-title":"Diacylglycerol triggers Rim101 pathway\u2013dependent necrosis in yeast: a model for lipotoxicity","volume":"25","author":"P Rockenfeller","year":"2018","journal-title":"Cell Death Differ"},{"key":"pone.0295244.ref034","doi-asserted-by":"crossref","first-page":"e22775","DOI":"10.1371\/journal.pone.0022775","article-title":"Increased Diacylglycerols Characterize Hepatic Lipid Changes in Progression of Human Nonalcoholic Fatty Liver Disease; Comparison to a Murine Model","volume":"6","author":"DL Gorden","year":"2011","journal-title":"PLOS ONE"},{"key":"pone.0295244.ref035","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nm0410-400","article-title":"Diacylglycerol-mediated insulin resistance","volume":"16","author":"DM Erion","year":"2010","journal-title":"Nat Med"},{"key":"pone.0295244.ref036","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"MC Petersen","year":"2017","journal-title":"Trends Pharmacol Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T18:31:45Z","timestamp":1701455505000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295244"}},"subtitle":[],"editor":[{"given":"Juan J","family":"Loor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295244","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}